期刊文献+

胃癌组织Akt和p-Akt蛋白及耐药相关蛋白表达临床意义的研究 被引量:3

Correlations between the expressions of Akt,p-Akt and P-gp,Gst-pi in gastric cancer
原文传递
导出
摘要 目的:检测胃癌组织Akt和p-Akt蛋白与胃癌生物学行为的相关性,及其与耐药相关蛋白P-gp和Gst-pi表达的相互关系。方法:将124例胃癌标本和16例正常胃黏膜标本制作成组织芯片,应用免疫组织化学SP法检测Akt、p-Akt、P-gp及Gst-pi蛋白的表达。同时利用蛋白质印迹法检测Akt、p-Akt、P-gp及Gst-pi在胃癌耐药细胞系SGC7901/ADR及其亲本细胞中的表达。结果:Akt和p-Akt在胃癌组织中的阳性表达率分别为82.3%和71.0%,显著高于正常胃黏膜,且两者表达均与胃癌的TNM分期有关(P<0.05)。p-Akt和P-gp表达成正相关,与Gst-pi表达无关,而Akt与P-gp、Gst-pi表达均无关。蛋白质印迹法结果提示,p-Akt在SGC7901/ADR中的表达显著高于其亲本细胞,而Akt在胃癌耐药和亲本细胞中的表达差异无统计学意义。结论:p-Akt过度表达可能参与P-gp介导的多药耐药,为临床采用Akt抑制剂以增加胃癌细胞的化疗敏感性提供了依据。 OBJECTIVE: To study the correlations between Akt,p-Akt expression levels and the biological behavior of gastric cancer, and explore the interrelations between expressions of Akt,p-Akt and P-gp,Gst-pi. METHODS: The expressions of Akt,p-Akt and P-gp,Gst-pi in gastric cancer (n= 124) and normal gastric mucosa (n=16) were detected by immunohistoehemical staining on tissue microarray sections. Western blot was employed to detect the expressions of Akt, p-Akt and P-gp, Gst-pi in SGC7901 and SGC7901/ADR cells. RESULTS: The expression levels of Akt (82.3%) and p-Akt (71.0%) in gastric cancer were higher than those in normal gastric mucosa (P〈0.05). The expression levels of Akt and p-Akt were strongly correlated with the clinical stages (P〈0.05). The expression of p-Akt,but not Akt, in gastric cancer had a positive correlation with that of P-gp. CONCLUSIONS: Multiple drug resistance in gastric cancer by P-gp mediated is strongly correlated with the expression of p Akt. Thus, it is of great importance to develop new compounds or strategies that are capable of circumventing P-gp mediated MDR with Akt interfering agents.
出处 《中华肿瘤防治杂志》 CAS 2009年第8期565-567,577,共4页 Chinese Journal of Cancer Prevention and Treatment
基金 国家自然科学基金(30770993) 辽宁省科技攻关计划(2004225004-11)
关键词 胃肿瘤 组织芯片 AKT P-AKT 多药耐药相关蛋白质类 stomach neoplasms tissue microarray Akt p-Akt multidrug resistance associated proteins
  • 相关文献

参考文献14

  • 1Kim C S, Vasko V V, Kato Y, et al. AKT activation promotes metastasis in a mouse model offollicular thyroid carcinoma[J]. Endocrinology, 2005,146 (10) : 4456-4463.
  • 2Lin H L, Yang M H, Wu C W, et al. 2 Methoxyestradiol attenuates phosphatidylinositol 3 kinase/Akt pathway-mediated metastasis of gastric cancer[J]. Int J Cancer,2007,121(11) :2547- 2555.
  • 3Lane D, Robert V, Grondin R, et al. Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells[J]. Int J Cancer,2007,121(6):1227-1237.
  • 4Lim W T, Zhang W H, Miller C R, et al. PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer[J]. Oncol Rep, 2007,17(4) : 853-857.
  • 5Choi B H, Kim C G, Lim Y, et al. Curcumin down-regulates the muhidrug resistance mdrlb gene by inhibiting the PI3K/ Akt/NF kappa B pathway[J]. Cancer Lett,2008,259(1):111- 118.
  • 6Barancik M, Bohacova V, Sedlak J, et al. LY294002, a specific inhibitor of PI3K/Akt kinase pathway, antagonizes P-glycoprotein-mediated multidrug resistanee[J]. Eur J Pharm Sci, 2006, 29(5):426-434.
  • 7马艳菊,胡雪君,刘云鹏,宋娜,侯科佐,张晔.非小细胞肺癌组织GST-π表达及其临床意义的研究[J].中华肿瘤防治杂志,2008,15(12):910-912. 被引量:4
  • 8Qu X, Liu Y, Ma Y, et ah Up regulation of the Cbl family of ubiquitin ligases is involved in ATRA and bufalin-induced cell adhesion but not cell differentiation[J]. Biochem Biophys Res Commun, 2008,367( 1 ) : 183-189.
  • 9Kobayashi I, Semba S, Matsuda Y, et al. Significance of Akt phosphorylation on tumor growth and vascular endothelial growth factor expression in human gastric carcinoma[J]. Pathobiology,2006,73(1) :8-17.
  • 10Hanada M, Feng J, Hemmings B A. Structure, regulation and function of PKB/AKT a major therapeutic target[J]. Biochim Biophys Acta, 2004,1697 (1-2) : 3-16.

二级参考文献23

共引文献9

同被引文献17

  • 1张伟.生物荧光肿瘤体外药敏检测技术的临床应用[J].中华检验医学杂志,2005,28(12):1316-1319. 被引量:9
  • 2廖永德,周晟,赵金平,袁永辉,黄畦,Doris Mayer.IGF信号通路关键蛋白IGF1、IGF1R和AKT在原发性肺腺癌中的表达及意义[J].实用肿瘤杂志,2006,21(1):15-19. 被引量:17
  • 3Li R, Pourpak A, Morris SW, et aL Inhibition of the insulin - like growth faetor - 1 receptor(IGF1R) Tyosine kinase as a novel eane- er therapy approach [J]. J Med Chem, 2009,52 ( 16 ) : 4981 - 5004.
  • 4Calakovie S, Lukie V, Mitrovie L, et al. Prognostic value of CM25 ki- netics and half- life in advanced ovarian cancer [ J ]. Int J Biol Mark- er, 2000,15 (2) : 147.
  • 5Neubauer H, Stefanova M, Solomayer E, et al. Predicting resistance to platinum - containing chemotherapy with the ATP tumor chemo- sensitivity assay in primary ovarian cancer [ J ]. Anticancer Res, 2008,28(2A) :949 -955.
  • 6Cheng JQ,Jiang X, Fraser M, et al. Role of X - linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer:possible in-volvement of phosphoinositide - 3 kinase/AKT pathway [ J ]. Drug Resist Updat,2002,5(3 -4) :131 - 146.
  • 7Eckstein N, Servan K, Hildebrandt B, et al. Hyperactivation of the insulin - like growth factor receptor I signaling pathway is an essen-tim event for cisplatin resistance of ovarian cancer cells[ J]. Cancer Res,2009,69 (7) :2996 - 3003.
  • 8Li R,Pourpak A, Morris SW, et al. Inhibition of the insulin-likegrowth factor-1 receptor (IGF1R) Tyosine kinase as a novelcancer therapy approach[J]. J Med Chem, 2009, 52 ( 16) : 4981-5004.
  • 9Neubauer H, Stefanova M, Solomayer E, et al. Predicting resist-ance to platinum-containing chemotherapy with the ATP tumorchemosensitivity assay in primary ovarian cancer[J]. AnticancerRes,2008,28(2A) :949-955.
  • 10Cheng JQ,Jiang X,Fraser M’et al. Role of X-linked inhibitor ofapoptosis protein in chemoresistance in ovarian cancer: possibleinvolvement of phosphoinositide-3 kinase/AKT pathway [J].Drug Resist Updat’2002,5(3-4) :131-146.

引证文献3

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部